NKTX
Nkarta Inc
NASDAQ: NKTX · HEALTHCARE · BIOTECHNOLOGY
$2.69
-2.89% today
Updated 2026-04-29
Market cap
$201.75M
P/E ratio
—
P/S ratio
1,000,000.00x
EPS (TTM)
$-1.41
Dividend yield
—
52W range
$2 – $4
Volume
0.8M
Nkarta Inc (NKTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.55M | $115385.00 | $385.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | -98.2% | -99.7% | -100.0% | — | — | — | — |
| Cost of revenue | $4.25M | $17217.00 | $1.05M | $2.12M | $6.57M | $5.87M | $9.15M | $9.19M |
| Gross profit | $2.30M | $98168.00 | $-1.05M | $-2.12M | $-6.57M | $-5.87M | $-9.15M | $-9.19M |
| Gross margin | 35.1% | 85.1% | -272207.8% | — | — | — | — | — |
| R&D | $4.25M | $17.22M | $36.22M | $63.41M | $90.90M | $90.90M | $96.74M | $90.43M |
| SG&A | $2.65M | $5.25M | $15.29M | $23.02M | $28.06M | $34.88M | $31.45M | $31.57M |
| Operating income | $-356449.00 | $-22.35M | $-51.51M | $-86.43M | $-118.95M | $-131.65M | $-128.19M | $-121.21M |
| Operating margin | -5.4% | -19368.7% | -13378701.3% | — | — | — | — | — |
| EBITDA | $-91289.00 | $-20.05M | $-50.72M | $-84.67M | $-116.32M | $-120.48M | $-119.04M | $-112.01M |
| EBITDA margin | -1.4% | -17376.4% | -13174545.5% | — | — | — | — | — |
| EBIT | $-274503.00 | $-20.60M | $-51.51M | $-86.43M | $-118.95M | $-126.35M | $-128.19M | $-121.21M |
| Interest expense | $0.00 | $473000.00 | $313000.00 | $2.11M | $5.59M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-274503.00 | $-21.08M | $-91.36M | $-83.95M | $-119.42M | $-117.50M | $-108.79M | $-104.08M |
| Net income growth (YoY) | — | -7577.8% | -333.5% | +8.1% | -42.3% | +1.6% | +7.4% | +4.3% |
| Profit margin | -4.2% | -18265.7% | -23730129.9% | — | — | — | — | — |